Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

医学 催眠药 福尔菲里 贝伐单抗 内科学 安慰剂 肿瘤科 二线疗法 结直肠癌 奥沙利铂 癌症 总体生存率 化疗 病理 替代医学
作者
Josep Tabernero,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannová,G. Bodoky,Rocio García‐Carbonero,Tudor‐Eliade Ciuleanu,David C. Portnoy,Eric Van Cutsem,Axel Grothey,Jana Prausová,Pilar García‐Alfonso,Kentaro Yamazaki,Philip R. Clingan,Sara Lonardi,Tae Won Kim,Lorinda Simms,Shao-Chun Chang,Federico Nasroulah
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (5): 499-508 被引量:866
标识
DOI:10.1016/s1470-2045(15)70127-0
摘要

Background Angiogenesis is an important therapeutic target in colorectal carcinoma. Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of VEGF receptor 2. We assessed the efficacy and safety of ramucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Methods Between Dec 14, 2010, and Aug 23, 2013, we enrolled patients into the multicentre, randomised, double-blind, phase 3 RAISE trial. Eligible patients had disease progression during or within 6 months of the last dose of first-line therapy. Patients were randomised (1:1) via a centralised, interactive voice-response system to receive 8 mg/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every 2 weeks until disease progression, unacceptable toxic effects, or death. Randomisation was stratified by region, KRAS mutation status, and time to disease progression after starting first-line treatment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01183780.ld Findings We enrolled 1072 patients (536 in each group). Median overall survival was 13·3 months (95% CI 12·4–14·5) for patients in the ramucirumab group versus 11·7 months (10·8–12·7) for the placebo group (hazard ratio 0·844 95% CI 0·730–0·976; log-rank p=0·0219). Survival benefit was consistent across subgroups of patients who received ramucirumab plus FOLFIRI. Grade 3 or worse adverse events seen in more than 5% of patients were neutropenia (203 [38%] of 529 patients in the ramucirumab group vs 123 [23%] of 528 in the placebo group, with febrile neutropenia incidence of 18 [3%] vs 13 [2%]), hypertension (59 [11%] vs 15 [3%]), diarrhoea (57 [11%] vs 51 [10%]), and fatigue (61 [12%] vs 41 [8%]). Interpretation Ramucirumab plus FOLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma. No unexpected adverse events were identified and toxic effects were manageable. Funding Eli Lilly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Liufgui应助机灵的觅山采纳,获得10
1秒前
1秒前
上官若男应助Kris采纳,获得10
2秒前
酷波er应助追寻书白采纳,获得10
3秒前
4秒前
5秒前
小北完成签到,获得积分10
7秒前
李健应助Ch_7采纳,获得10
7秒前
7秒前
8秒前
10秒前
临渊之何发布了新的文献求助10
11秒前
雪山飞龙发布了新的文献求助10
12秒前
852应助耍酷问兰采纳,获得10
13秒前
自信雅琴完成签到,获得积分10
13秒前
杨123发布了新的文献求助10
14秒前
wanci应助相信未来采纳,获得10
14秒前
nczpf2010完成签到,获得积分10
15秒前
111111111发布了新的文献求助10
15秒前
冷艳的姿发布了新的文献求助10
15秒前
16秒前
学术渣渣发布了新的文献求助10
17秒前
17秒前
量子星尘发布了新的文献求助10
18秒前
男子无才便是德完成签到,获得积分10
19秒前
19秒前
yuhangcao完成签到,获得积分10
19秒前
乐乐应助皮老师采纳,获得10
19秒前
SciGPT应助雪山飞龙采纳,获得10
20秒前
20秒前
隐形曼青应助anna采纳,获得10
21秒前
谦让成协完成签到,获得积分10
22秒前
SuperD发布了新的文献求助10
22秒前
sumugeng完成签到,获得积分10
23秒前
耍酷问兰发布了新的文献求助10
23秒前
23秒前
小宋爱科研完成签到 ,获得积分10
25秒前
YJ888发布了新的文献求助10
25秒前
赘婿应助孙亦沈采纳,获得10
26秒前
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073